End points and United States Food and Drug Administration approval of oncology drugs.
about
Prophylactic mastectomy for the prevention of breast cancerSurrogate end points of quality of life assessment: have we really found what we are looking for?Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision makingGuidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)γδ T cells in cancer immunotherapyTargeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancerSurrogate outcomes in neurology, psychiatry, and psychopharmacologyTime-dependent endpoints as predictors of overall survival in multiple myelomaMissing data and censoring in the analysis of progression-free survival in oncology clinical trials.Response criteria for glioma.Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study.Improving health care efficiency and quality using tablet personal computers to collect research-quality, patient-reported dataEfficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysisSurrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologistsDoes change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statementPatient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer.Improving CT prediction of treatment response in patients with metastatic colorectal carcinoma using statistical learning theoryOvercoming barriers to the implementation of patient-reported outcomes in cancer clinical trials: the PROMOTION Registry.Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer.Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation.Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.Rethinking clinical trials for cytostatic drugs.Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.In the end what matters most? A review of clinical endpoints in advanced breast cancer.Endpoints in advanced breast cancer: methodological aspects & clinical implications.Medical imaging in new drug clinical development.Assessing tumor-related signs and symptoms to support cancer drug approval.Prostate cancer clinical trial end points: "RECIST"ing a step backwards.Quantified visual scoring of metastatic melanoma patient treatment response using computed tomography: improving on the current standardDevelopment and use of biomarkers in oncology drug development.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
P2860
Q24236609-D2D0E742-3618-4F6B-B946-39D0BC07CD55Q24800039-466D42D4-4CF8-4BA8-866C-604D68BA67A3Q26852751-3E52C2A7-BF05-4A5C-8D33-6240EC81E007Q27027579-727FE812-9979-4C2F-B701-341F59DE057FQ27028138-B6087594-CE8C-4157-AB4E-BF06A701137AQ28068988-62BD1CC8-E424-489F-902A-FFAC239382E7Q28659468-1652B86B-31F1-40A7-8DA0-5F777FB57984Q30473416-72141FC2-15B1-4F7F-AC09-798E20639624Q30538040-006B5DEC-5E12-4B78-834C-CC0F30B8E013Q30662279-75F06E89-2096-4DA1-99F2-E4847DB52C3DQ31172444-87E84313-4CBB-4723-B9F6-CB3066EC156DQ33326482-D0DD9D4C-EA1B-4F7A-AF8B-5C634E5F1F5AQ33365415-70EB66B6-AD67-4945-BDDE-6E525321CE20Q33430139-1509A0A8-637D-4670-9257-CEAB4C2A3376Q33600372-A5FB7736-D7A7-4C0B-B8A1-542CEA486A61Q33613709-6E00EA6D-5581-4107-9748-CB4646053BF8Q33622648-B01EF6AB-084F-4E91-B6A7-82ADD7E07B0FQ33652833-134299CE-9240-452E-9278-630B2C49C4B1Q33723692-CCCCE816-BE97-4775-91C5-B7CFBECC2936Q33766595-EB219173-F5ED-47E2-9A59-82A6E03AB8CFQ33780250-32DD2678-0F56-4D8A-A079-B0AD492EFECCQ33800697-1702A05A-9A61-46F4-9C54-686A2BCB03E4Q33916064-34568787-2D6C-4597-B2F9-8E22C381A777Q33921813-7169296F-C856-4F2A-876C-CE73CF7FF8CFQ34005168-27EE4DF2-B85D-49F8-A493-B1FEF7636210Q34049406-3106BBFD-58EB-4A75-80CA-F36EF1BCD341Q34381979-8CEF0562-4499-4BFA-AEE4-54C8AEB4C577Q34434814-B73B69F4-9AFC-4ED6-B1A4-812CA18942A1Q35166825-8D9031A9-1ACD-40E0-BF40-1554AC331209Q35214578-3A66F059-811E-4DA2-8D8E-9B2819BFDC64Q35583788-3EC1DCF2-5DAB-4359-87C0-09DD051643A0Q35584322-46D8B786-4CF6-436E-9A14-3EBBE94B024DQ35611036-C7D1A575-C54D-4EDB-8E33-096858512DDBQ35667744-029DF791-80EC-488B-8A12-008DCFADB0A8Q35694266-9986676D-FC50-4B1A-97A0-B4AE6897EBD7Q35751894-C12C3345-66A1-4590-ABAE-CA4709AA1C1AQ35809822-CD76BC8F-2D5E-49ED-865D-F1C96F79CDCDQ35812532-C07CF66F-9273-4FC7-A019-F320BAB13695Q35827606-E8A5F216-2D6D-4EE1-9902-2FBF0B36A99FQ35909843-341A78C2-5249-4F63-8937-3B13409059AA
P2860
End points and United States Food and Drug Administration approval of oncology drugs.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
End points and United States Food and Drug Administration approval of oncology drugs.
@en
End points and United States Food and Drug Administration approval of oncology drugs.
@nl
type
label
End points and United States Food and Drug Administration approval of oncology drugs.
@en
End points and United States Food and Drug Administration approval of oncology drugs.
@nl
prefLabel
End points and United States Food and Drug Administration approval of oncology drugs.
@en
End points and United States Food and Drug Administration approval of oncology drugs.
@nl
P2093
P356
P1476
End points and United States Food and Drug Administration approval of oncology drugs.
@en
P2093
Grant Williams
John R Johnson
Richard Pazdur
P304
P356
10.1200/JCO.2003.08.072
P407
P577
2003-04-01T00:00:00Z